Publikationen von 0000-0001-5818-5392
(ORCID: 0000-0001-5818-5392)

Weller, J. , Schäfer, N., Schaub, C., Tzaridis, T. , Zeyen, T., Schneider, M. , Potthoff, A. L., Giordano, F. A. , Steinbach, J. P., Zeiner, P. S., Kowalski, T., Sabel, M. , Hau, P., Krex, D., Grauer, O., Goldbrunner, R., Schnell, O., Tabatabai, G. , Ringel, F., Schmidt-Graf, F., Brehmer, S., Tonn, J. C., Bullinger, L. , Vajkoczy, P., Glas, M., Vatter, H., Herrlinger, U. und Seidel, C. (2023) Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. Journal of Neuro-Oncology 161 (1), S. 147-153. Volltext nicht vorhanden.

Weller, Johannes , Schäfer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael , Hau, Peter , Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Güresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich und Schneider, Matthias (2022) Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. Journal of Neuro-Oncology 159 (1), S. 95-101.

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert , Weller, Johannes , Mack, Frederic, Tzaridis, Theophilos, Bähr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh , Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin und Herrlinger, Ulrich (2019) Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. Journal of Neuro-Oncology 144 (3), S. 501-509. Volltext nicht vorhanden.

Weller, Johannes , Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert , Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich und Schäfer, Niklas (2019) Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology 20 (10), S. 1444-1453. Volltext nicht vorhanden.

Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter , Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert , Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schäfer, Niklas, Kebir, Sied, Weller, Johannes , Schaub, Christina, Stummer, Walter, Tonn, Jörg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang , Weller, Michael , Fimmers, Rolf, Schmid, Matthias , Hattingen, Elke , Pietsch, Torsten, Coch, Christoph und Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393 (10172), S. 678-688. Volltext nicht vorhanden.